SkinAxis LLC — Department of Health and Human Services SBIR Phase I: 102
SkinAxis LLC — SBIR Phase I award from Department of Health and Human Services.
- Amount
- $299,675
- Agency
- Department of Health and Human Services · National Institutes of Health
- Program / Phase
- SBIR · Phase I
- Topic
- 102
- Solicitation
- PA16-302
- NAICS
- —
- Place of performance
- NJ
- Period
- 2017-09-25 → 2019-02-28
Description
Abstract Breast cancer BC is the most common cancer among women Viruses have long been suspected as a cause of breast cancer However despite the identification of virions in human BC cells and human milk and numerous studies that suggest possible connection between breast cancer and Epstein Barr virus EBV mouse mammary tumor virus MMTV and human papilloma virus HPV the tumorigenic potential of these viruses has not been proven in BC Our preliminary data offer the compelling evidence that a filterable transforming agent is present in the supernatant of a BC cell line that we established in vitro This agent is transmissible transforms primary human mammary epithelial cells in vitro and confers these cells the tumorigenic phenotype in vivo Based on preliminary results we hypothesize that a virus accounts for the observed human mammary epithelial cells transforming activity This application has the very focused objective of isolating and characterizing this transforming agent employing comprehensive and complementary proteomics and transcriptomics approaches and in vitro genetic validation systems The results of this study will provide the first evidence of a human mammary epithelial cells transforming agent and shed new light into tumor pathogenesis Importantly the isolation of a BC transforming virus will allow the development of novel diagnostic tools vaccines and specific inhibitors of significant therapeutic value Cells from breast cancer tissue isolated in our laboratory release an oncogenic virus that causes tumor in primary mammary cells We will isolate and characterize this viral agent Its identification will allow the development of diagnostics vaccines and antiviral molecules to prevent or treat breast cancer